| ABSTRACT Objective:To study the influences of butylphthalide adjuvant therapy on endothelial progenitor cells (EPCs), basic fibroblast growth factor (bFGF) and collateral circulation in patients with progressive cerebral infarction. Methods: The clinical data of 89 patients with progressive cerebral infarction were analyzed retrospectively from January 2015 to July 2017. All patients were divided into control group (n=40) and butylphthalide group (n=49) according to the method of medication. The patients in control group were received conventional treatment, the patients in butylphthalide group were added to injection of butylphthalide 25 mg, intravenous drip, 1 time/day. Both groups were treated for 14d continuously. NIHSS score, Barthel index, infarct volume, clinical efficacy and peripheral blood EPCs quantity, bFGF content and collateral circulation opening rate before and after treatment were observed and compared in two groups. Results: The total effective rate in butylphthalide group was 83.7%, and the collateral circulation opening rate was 79.6%, which were significantly higher than control group (P<0.05). After the treatment, the NIHSS score reduced significantly (P<0.05) while the Barthel index increased significantly (P<0.05), and the area of infarct reduced significantly in two groups (P<0.05). These indexs in butylphthalide group were superior to the control group (P<0.05). The EPCs quantity and bFGF content after treatment were significantly higher than those before treatment in two groups(P<0.05), and the increases in daliphthalein group were greater than those in control group (P<0.05). Conclusion:The effect of butylphthalide adjuvant therapy on progressive cerebral infarction was obvious. It could significantly increase the number of EPCs and bFGF content in peripheral blood of patients, which was beneficial to the establishment of collateral circulation and the improvement of neurological function. |
